<DOC>
	<DOCNO>NCT00060398</DOCNO>
	<brief_summary>RATIONALE : Epoetin alfa may stimulate red blood cell production may help improve cancer-related anemia fatigue . Steroid therapy dexamethasone may increase effectiveness epoetin alfa . It yet know epoetin alfa effective without dexamethasone treat anemia-related fatigue patient prostate cancer . PURPOSE : This randomized phase III trial study epoetin alfa dexamethasone see well work compare epoetin alfa alone treat anemia-related fatigue patient prostate cancer refractory treatment hormone therapy .</brief_summary>
	<brief_title>Epoetin Alfa With Without Dexamethasone Treating Fatigue Anemia Patients With Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect epoetin alfa without dexamethasone level cancer-related fatigue measure FACIT fatigue subscale , patient hormone-refractory prostate cancer . - Compare effect regimens increase hemoglobin level patient . - Compare effect regimens palliation disease-related symptom functional status overall quality life patient . - Compare survival rate regimen patient . - Compare toxicity profile regimens patient . - Determine incidence adrenal suppression patient receive dexamethasone therapy . OUTLINE : This randomize , multicenter study . Patients stratify accord usual fatigue severity Brief Fatigue Inventory numerical scale ( 3-6 v 7-10 ) hemoglobin level ( 8-10 g/dL v 10.1-11.9 g/dL ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive epoetin alfa subcutaneously week . - Arm II : Patients receive epoetin alfa arm I oral dexamethasone day . In arm , treatment continue 12 week absence unacceptable toxicity . Quality life fatigue assess baseline 4 , 8 , 12 week . Patients follow 3 year . PROJECTED ACCRUAL : A total 282 patient ( 141 per treatment arm ) accrue study within approximately 3 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer Hormonerefractory disease evidence progression bone scan CT scan rise prostatespecific antigen Prior bilateral orchiectomy OR primary hormonal therapy ( e.g. , estrogen therapy luteinizing hormonereleasing hormone analog [ LHRH ] flutamide ) evidence treatment failure Concurrent continual LHRH agonist therapy ( e.g. , depot leuprolide goserelin ) require patient undergone bilateral orchiectomy Must anemia hemoglobin ≥ 8 g/dL &lt; 12 g/dL within past 14 day Must iron replete ( i.e. , ferritin &gt; 50 ng/mL ) within past 30 day Presence fatigue usual fatigue severity ≥ 3 010 numerical scale Brief Fatigue Inventory within past 14 day PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 03 Life expectancy Not specify Hematopoietic See Disease Characteristics No disseminate intravascular coagulation No autoimmune hemolytic anemia Hepatic AST ALT ≤ 2 time upper limit normal No prior hemochromatosis iron intolerance Renal Creatinine &lt; 2.5 mg/dL Cardiovascular Adequate blood pressure ( i.e. , systolic blood pressure &lt; 140 mm Hg diastolic blood pressure &lt; 90 mm Hg ) ( treat untreated ) No history thromboembolic event No unstable angina No poorly control cardiac disease Other Fertile patient must use effective contraception Able read , understand , answer question symptom quality life study instrument No ongoing chronic hemorrhage ( e.g. , gross hematuria due advanced prostate cancer ) * NOTE : *Microscopic hematuria allow No acute subacute illness may require transfusion No gastrointestinal bleeding No active systemic infection No known suspect hypersensitivity human albumin No know suspect hypersensitivity mammalian cellderived product No uncontrolled diabetes PRIOR CONCURRENT THERAPY : Biologic therapy More 30 day since prior epoetin alfa Chemotherapy More 21 day since prior chemotherapy No 2 different type prior chemotherapy regimen hormonerefractory prostate cancer Endocrine therapy See Disease Characteristics More 30 day since prior corticosteroid hormonerefractory prostate cancer Episodic use lowdose steroid cause allowed Radiotherapy More 21 day since prior radiotherapy Concurrent radiotherapy allow Surgery See Disease Characteristics Other More 8 week since prior blood transfusion No concurrent oral intravenous antibiotic</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>anemia</keyword>
	<keyword>fatigue</keyword>
</DOC>